Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells

Pharmacological Reports

Volumn 65, Issue 4, 2013, Pages 884-890

  Dorecka, Mariola ^a   Siemianowicz, Krzysztof ^a   Francuz, Tomasz ^a   Garczorz, Wojciech ^a   Chyra, Agnieszka ^a   Klych, Agnieszka ^a   Romaniuk, Wanda ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adhesion molecules; AGE; Human retinal pigment epithelium; Incretins; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED ALBUMIN; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; PROTEIN SECRETION;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; PEPTIDES; RECEPTORS, IMMUNOLOGIC; RETINAL PIGMENT EPITHELIUM; SERUM ALBUMIN; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; VENOMS;

EID: 84886451568     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71069-7     Document Type: Article

References (45)

1. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y et al.: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendine-4. Diabetes, 2010, 59, 1030-1037.
2. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation, 2008, 117, 2340-2350.
3. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T et al.: Advanced glycation end products activate endothelium through signal-transduction receptor RAGE. A mechanism for amplification of inflammatory responses. Circulation, 2002, 105, 816-822.
4. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H: Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes, 1995, 44, 824-829.
5. Berg TJ, Dahl-Jorgensen K, Torjesen PA, Hanssen KF: Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care, 1997, 20, 1006-1008.
6. Brubaker PL: Incretin-based therapies: mimetics versus protease inhibitors. Trends Endocrinol Metab, 2007, 8, 240-245.
7. Chen S, Cohen MP, Ziyadeh FN: Amadori-glycated albumin in diabetic retinopathy: pathophysiologic connections. Kidney Int, 2000, Suppl 77, S 40-44.
8. Chen W, Esselman W, Jump DB. Busik JV: Antiinflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci, 2005, 46, 4342-4347.
9. Cohen MP, Ziyadeh FN, Chen S: Amadori-glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med, 2006, 147, 211-219.
10. Devine L, Lightman SL, Greenwood J: Role of LFA-1, ICAM-1, VLA-4 and VCAM-1 in lymphocyte migration across retinal pigment epithelial monolayers in vitro. Immunology, 1996, 88, 456-462.
11. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM: ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res, 1996, 62, 155-169.
12. Fosmark DS, Torjesen PA, Kilhovd BK, Berg TJ, Sandvik L, Hanssen KF, Agardh CD, Agardh E: Increased serum levels of the specific advanced end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism, 2006, 55, 232-236.
13. Gustavsson C, Agardh CD, Zetterqvist AV, Nilsson J, Agardh E, Gomez MF: Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia. PLoS One, 2010, 5, e12699.
14. Hernandez C, Burgos R, Canton A, Garcia-Arumi J, Segura RM, Simo R: Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care, 2001, 24, 516-521.
15. Hughes JM, Brink A, Witmer AN, Hanraads-de Riemer M, Klaassen I. Schlingemann RO: Vascular leucocyte adhesion molecules unaltered in the human retina in diabetes. Br J Ophthalmol, 2004, 88, 566-572.
16. Ibrahim AS, El-Remessy AB, Matragoon S, Zhang W, Patel Y, Khan S, Al-Gayyar MM, El-Shishtawy MM, Liou GI: Retinal microglial activation and inflammation induced by Amadori-glycated albumin in a rat model of diabetes. Diabetes, 2011, 60, 1122-1133.
17. Ishibashi Y, Matsui T, Takeuchi M. Yamagishi S: Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun, 2010, 391, 1405-1408.
18. Jakus V, Rietbrock N: Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res, 2004, 53, 131-142.
19. Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, Rudge J et al.: Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol, 2002, 160, 501-509.
20. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, Hanssen KF: Increased serum levels of the specific AGE-compund methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism, 2003, 52, 163-167.
21. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol, 2009, 5, 262-269.
22. Ma W, Lee SE, Guo J, Qu W, Hudson BI, Schmidt AM, Barile GR: RAGE ligand upregulation of VEGF secretion in APRE-19 cells. Invest Ophthalmol Vis Sci, 2007, 48, 1355-1361.
23. Mamputu JC, Renier G: Advanced glycation endproducts increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factorinduced ICAM-1 expression: inhibitory effect of antioxidants. J Leukoc Biol, 2004, 75, 1062-1069.
24. Matsuoka M, Ogata N, Minamino K, Matsumura M: Leukostasis and pigment epithelium-derived factor in rat models of diabetic retinopathy. Mol Vis, 2007, 13, 1058-1065.
25. Moore TCB, J.E. Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL et al.: The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci, 2003, 44, 4457-4464.
26. Nathanson D, Zethelius B, Berne C, Holst JJ, Sjöholm A, Nyström T: Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impared glucose tolerance but not with coronary heart disease. Diabetologia, 2010, 53, 277-280.
27. Olson JA, Whitelaw CM, McHardy KC, Pearson DW, Forrester JV: Soluble leucocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration. Diabetologia, 1997, 40, 1166-1171.
28. Platts KE, Benson MT, Rennie IG, Sharrard M, Rees RC: Cytokine modulation of adhesion molecule expression on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci, 1995, 36, 2262-2269.
29. Poon S, Birkett NR, Fowler SB, Luisi BF, Dobson CM, Zurdo J: Amyloidogenecity and aggregate cytotoxicity of human glucagon-like peptide-1 (hGLP-1). Protein Pept Lett, 2009, 16, 1548-1556.
30. Sampathkumar AB, Balasubramanyam M, Rema M: Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects. J Diabetes Complications, 2008, 22, 261-266.
31. Sampathkumar R, Balasubramanyam M, Rema M, Premanand C, Mohan V: A novel advanced glycation index and its association with diabetes and microangiopathy. Metabolism, 2005, 54, 1002-1007.
32. Schalkwijk CG, Lieuw-A-Fa M, van Hinsbergh VW, Stehouwer CD: Pathophysiological role of Amadoriglycated protein in diabetic microangiopathy. Semin Vasc Med, 2002, 2, 191-197.
33. Schmidt AM, Hofmann M, Taguchi A, Yan SD, Stern DM: RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost, 2000, 26, 485-493.
34. Schmidt AM, Stern D: Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep, 2000, 2, 430-436.
35. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor for RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest, 2001, 108, 949-955.
36. Siemianowicz K, Francuz T, Gminski J, Telega A, Syzdól M: Endothelium dysfunction markers in patients with diabetic reinopathy. Int J Mol Med, 2005, 15, 459-462.
37. Stern D, Yan SD, Yan SF, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev, 2001, 1, 1-15.
38. Stern D, Yan SD, Yan SF, Schmidt AM: Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev, 2002, 54, 1615-1625.
39. Tang S, Le-Ruppert KC, Gabel VP: Expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on proliferating vascular endothelial cells in diabetic epiretinal membranes. Br J Ophthalmol, 1994, 78, 370-376.
40. Thomas MC, Baynes JW, Thorpe SR, Cooper ME: The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets, 2005, 6, 453-474.
41. Thorpe SR, Baynes JW: Role of Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging, 1996, 9, 69-77.
42. Wendt T, Bucciarrelli L, Qu W, Lu Y, Stern DM, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep, 2001, 4, 228-237.
43. Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W: Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol, 2009, 247, 699-706.
44. Zhang Y, Zhang J, Wang Q, Lei X, Chu Q, Xu GT, Ye W: Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Invest Ophthalmol Vis Sci, 2011, 52, 278-285.
45. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X et al: Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation, 2003, 107, 2238-2243.